Latest Breaking News On - பெக்மேன் ஆராய்ச்சி நிறுவனம் - Page 1 : comparemela.com
Mini Brain Models Used To Study Alzheimer s and Test Drugs
technologynetworks.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technologynetworks.com Daily Mail and Mail on Sunday newspapers.
New discoveries reveal how acute myeloid leukemia walks line between growth and cell death
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Study Turns Central Dogma on Its Head
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.
The distinctive immuno-oncology RNA therapy targets multiple types of cancers.
Scopus BioPharma shares jumped 200% in the stock market on Monday morning.
Scopus BioPharma Inc. (NASDAQ: SCPS) said the U.S. Food and Drug Administration FDA approved its IND (investigational new drug) application on Monday for CpG-STAT3siRNA – its distinctive immuno-oncology RNA therapy that targets multiple types of cancers.
Impact on the share price
Following the announcement, Scopus BioPharma jumped roughly 200% in the stock market on Monday morning. The company touched a high of $15.42 per share (£10.90 per share) and is currently exchanging hands at $12.54 per share. In comparison, Scopus had started the year 2021 at a per-share price of $13.41.
(0)
VANCOUVER, BC, April 20, 2021 /PRNewswire/
Precision NanoSystems (PNI), a global leader in innovative solutions for genetic medicine development, today launched the GenVoy-ILM T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based
ex vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and reproducibly generate high yields of engineered primary human T cells using a simple workflow.
The GenVoy-ILM T Cell Kit for mRNA uses LNP designed to exploit endogenous uptake pathways to efficiently deliver mRNA into activated human primary T cells to mediate titratable, uniform protein expression levels with high cell viability. The mRNA-LNP are also compatible with established T cell culture media allowing rapid integration into existing workflows. The combination of non-disruptive mRNA delivery technology and seamless integration with cell culture protocols eliminates cell recovery times post-treatment to accelerate the production of T cell therapies.